StreetInsider.com News Articles

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Mon, 02 Mar 2026 16:01:00 -0500

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D. and Chief Scientific Officer Elizabeth Buck, Ph.D., are as follows:

46th Annual TD Cowen Healthcare Conference presentation at 1:10pm ET on Wednesday, March 4, 2026
25th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Wednesday, April 15, 2026

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Mon, 02 Mar 2026 16:01:00 -0500

46th Annual TD Cowen Healthcare Conference presentation at 1:10pm ET on Wednesday, March 4, 2026
25th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Wednesday, April 15, 2026

Form SCHEDULE 13G/A Black Diamond Therapeuti Filed by: Vestal Point Capital, LP

Tue, 17 Feb 2026 16:10:00 -0500

si-local-file:///var/storage/secattach/20260217/26012716.html

Form SCHEDULE 13G/A Black Diamond Therapeuti Filed by: Vestal Point Capital, LP

Tue, 17 Feb 2026 16:10:00 -0500

si-local-file:///var/storage/secattach/20260217/26012716.html

Form 4 Black Diamond Therapeuti For: Jan 21 Filed by: Buck Elizabeth

Fri, 23 Jan 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260123/25887080.html

Form 4 Black Diamond Therapeuti For: Jan 21 Filed by: Buck Elizabeth

Fri, 23 Jan 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260123/25887080.html

Form 4 Black Diamond Therapeuti For: Jan 21 Filed by: Yurasov Sergey

Fri, 23 Jan 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260123/25887082.html

Form 4 Black Diamond Therapeuti For: Jan 21 Filed by: Yurasov Sergey

Fri, 23 Jan 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260123/25887082.html

Form 4 Black Diamond Therapeuti For: Jan 21 Filed by: Velleca Mark A.

Fri, 23 Jan 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260123/25887083.html

Form 4 Black Diamond Therapeuti For: Jan 21 Filed by: Velleca Mark A.

Fri, 23 Jan 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260123/25887083.html

Form 4 Black Diamond Therapeuti For: Jan 21 Filed by: Hatzis-Schoch Brent

Fri, 23 Jan 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260123/25887084.html

Form 4 Black Diamond Therapeuti For: Jan 21 Filed by: Hatzis-Schoch Brent

Fri, 23 Jan 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260123/25887084.html

Form 4 Black Diamond Therapeuti For: Jan 21 Filed by: Jones Erika

Fri, 23 Jan 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260123/25887085.html

Form 4 Black Diamond Therapeuti For: Jan 21 Filed by: Jones Erika

Fri, 23 Jan 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260123/25887085.html

Black Diamond Therapeutics (BDTX) PT Lowered to $8 at Piper Sandler

Fri, 16 Jan 2026 08:35:44 -0500

Piper Sandler analyst Kelsey Goodwin lowered the price target on Black Diamond Therapeutics (NASDAQ: BDTX) to $8.00 (from $9.00) while maintaining a Overweight rating.

Why Jefferies sees these stocks as standout biotech plays in 2026

Tue, 23 Dec 2025 10:00:00 -0500

Jefferies recently laid out a roadmap for biotech in 2026, pointing to a mix of late-stage regulatory catalysts, underappreciated plays, and select turnaround opportunities as potential key drivers of stock performance.

Among its top ideas for 2026, the broker highlights Vera Therapeutics (NASDAQ: VERA) and Nuvation Bio (NYSE: NUVB).

Vera stands out for its positioning in IgA nephropathy, where the company is “threading the needle on optimal safety & efficacy” within the competitive BAFF/APRIL drug class,” analysts led by Farzin Haque wrote in a note.